That the CD3xEpCAM bispecific molecule could activate CD8+ T cells in vitro regardless of TCR specificity and reduce tumor growth in vivo even though optimal antibody architecture and affinity was not identified is in itself remarkable. Here, CD8A is linked to neoplasm.